Eliem halts Kv7 program, explores strategic alternatives including sale or merger

Climb Bio, Inc.

Halts further development of Kv7 program; shifts focus to maximizing shareholder value.
Engages Leerink Partners as strategic advisor to explore acquisition, merger, or business combination.
Reports preliminary unaudited cash, cash equivalents, and marketable securities of ~$102.6M as of June 30, 2023.
No timetable set for strategic review; no assurance any transaction will occur.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.